Financial results for the period ended September 30, 2026
As filed · Alivus Life Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
EarningsMajormateriality 75 out of 100
What happened
FactFinancial results for the period ended September 30, 2026. Board at its meeting held today approved the Unaudited Financial Results for the Second. The copy of the said Results and Limited Review Report of the Auditor is enclosed herewith.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
Watch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- Going forward, we continue to expect high single-digit revenue growth for FY’26, driven by strong and profitab (management committed by FY26)
- In about 1 to 1.5 years, we can get the project going. (management committed by H1 FY27)
Evidence
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +2 corroborating keywords; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%